Faeth Therapeutics (4070) Stock Overview

A clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. More details

4070 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Analysts in good agreement that stock price will rise by 64.3%

Risk Analysis

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

4070 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW431,284 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

431,284 investors already sharing narratives

View all narratives

Faeth Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Faeth Therapeutics
Historical stock prices
Current Share Price	US$29.80
52 Week High	US$34.60
52 Week Low	US$24.20
Beta	-0.28
1 Month Change	10.37%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	23.14%

Recent updates

Shareholder Returns

	4070	DE Biotechs	DE Market
7D	-11.3%	2.1%	-0.6%
1Y	n/a	-0.5%	4.0%

Return vs Industry: Insufficient data to determine how 4070 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 4070 performed against the German Market.

Price Volatility

Is 4070's price volatile compared to industry and market?
4070 volatility
4070 Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.5%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.7%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 4070's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 4070's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	29	Anand Parikh	www.faeththerapeutics.com

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors.

Faeth Therapeutics, Inc. Fundamentals Summary

How do Faeth Therapeutics's earnings and revenue compare to its market cap?
4070 fundamental statistics
Market cap	€776.14m
Earnings (TTM)	-€170.23m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-4.6x

P/E Ratio

Is 4070 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4070 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$195.53m
Earnings	-US$195.53m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-7.57
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 4070 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/21 09:07
End of Day Share Price	2026/09/18 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Faeth Therapeutics, Inc. is covered by 19 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jack Allen	Baird
Zhiqiang Shu	Berenberg
Suranjit Mukherjee	BTIG

Faeth Therapeutics, Inc.DB:4070 Stock Report